Read more about Intas Pharma files draft prospectus for IPO on Business Standard. Drug maker Intas Pharmaceuticals today said it has filed. Intas Pharmaceuticals, has filed its draft red herring prospectus (DRHP) with Securities and Exchange Board of India (SEBI) for an initial public. Intas Pharma DRHP News: Latest and Breaking News on Intas Pharma DRHP. Explore Intas Pharma DRHP profile at Times of India for photos, videos and latest .
|Published (Last):||9 October 2006|
|PDF File Size:||17.84 Mb|
|ePub File Size:||18.36 Mb|
|Price:||Free* [*Free Regsitration Required]|
Sun Pharma in early talks to buy Intas Pharma. Drugs sold sans regulator’s nod, safety studies. Please note that comments are moderated and are generally published if they intax on-topic and not abusive.
It has also extended its presence into other therapy areas such as gynecology, infertility, drjp and the respiratory. All rights reserved Disclaimer. Email Enter a valid email address. Binish Hasmukh Chudgar, Mr. Drug-maker Intas Pharmaceuticals has merged all its group companies and subsidiaries over concerns about low profits. Subscribe to BioSpectrum India.
Intas Pharmaceuticals files DRHP for IPO
Intas Pharma inats first etanercept biosimilar. It is currently ranked as the 12th largest pharmaceutical company in the country with a 2. Intas Pharma eyes hospitals in Europe, US. Mon, Dec 31, Updated Its products are marketed in over 60 countries, either directly, through its subsidiaries or indirectly, through supply, distribution and other arrangements with various leading global pharmaceutical companies.
ChrysCap backs Curatio in latest pharma bet.
Intas Pharmaceuticals files DRHP for IPO –
New Delhi, May 26 RPG Life Sciences has sold its Gujarat-based biotechnology unit to Intas Pharmaceuticals for Rs 25 crore to focus on core areas of business and improve long-term competitiveness in a rapidly changing market. In what could further strengthen its business in European and non-European countries, Ahmedabad based Intas Pharmaceuticals Ltd has acquired hospital business of Combino Pharm in Spain and Portugal for an undisclosed sum.
Intas to buy Teva’s UK, Ireland assets for mn pounds. Please click here to Sign-in or Sign-up. MCI to probe foreign jaunts by MP doctors. The IPO will be made through a public issue of equity shares of face value of Rs.
The promoters of the company are Mr. Intas Pharma merges group companies, subsidiaries. Rahul Gandhi listed as ‘non-Hindu’. Visit Our Digital Magazine: Chandra kicks off divestment plan.
Intas Pharma files for an IPO
Medical Council of India MCI will investigate a complaint against 11 doctors from Madhya Pradesh who are charged with accepting foreign jaunts sponsored by pharmaceutical company. Enquiry Thanks for contacting us! Intas Pharma is a vertically integrated Indian pharmaceutical company with global operations, engaged in the development, manufacture and marketing of pharmaceutical formulation. Hyderabad-based pharma giant Aurobindo snaps up Portuguese co for Rs crore.
Intas Pharma files ddrhp an IPO. Web Interface Conceived and Powered By: From around the Web.
The Ahmedabad-based company is considering licensing agreements with hospital-based businesses in these markets. Jntas Pharma buys Spanish company’s hospital business. The company is present in various major therapy areas such as those relating to neurology, psychiatry, cardiology, pain management, gastroenterology, diabetology, nephrology, urology, anti-infective therapy, dermatology, gynecology, respiratory system, oncology, critical care and ophthalmology with a strong focus on chronic therapy areas relating to neurology, psychiatry, cardiology and diabetology.
According to sources, the company has begun the groundwork for the IPO and approached merchant bankers a couple of months ago. Monday, 31 December We will get in touch with you shortly. Sources said the group has started a process to sell drug discovery services company Advinus Therapeutics, drawing interest from private equity funds Kedaara Capital and True North as well as from strategic players, GVK Biosciences and Lambda, a unit of Intas Pharma.
Please fill the all fields. At present, domestic companies are marketing their products only in emerging markets, but the largest and most lucrative market for all pharmaceuticals — the US — is the next stop. Desi pharma companies inyas in biosimilars globally.